Epic Brings Cash and Insurance Drug Prices Into the Prescribing Workflow
Epic is building a new Prescription Marketplace tool that will let clinicians compare prescription cash prices and insurance costs across pharmacies before a patient leaves the office. The rollout is slated for summer 2027, and the goal is straightforward: reduce the number of prescriptions that never get filled because the patient cannot afford them.
Cost remains one of the most persistent drivers of medication nonadherence in U.S. care. More than 40% of American adults do not take medications as prescribed because of price concerns, a gap that can quietly turn a well-chosen therapy into an ineffective one. If a patient never starts treatment, the pharmacology is irrelevant; the prescription ends at the counter instead of the bloodstream.
Epic’s new feature is designed to make price visible at the same moment the drug is selected. It will surface pharmacy cash prices alongside what the patient would pay using insurance, creating a side-by-side view that can change the decision before the prescription is signed. For clinicians, that means fewer blind spots. For patients, it means fewer surprises when the pharmacy calls or the copay lands in the app.
Real-Time Price Checks Could Change Prescribing Behavior
The new tool builds on Epic’s existing Real-Time Prescription Benefit feature, which already shows clinicians what a patient would pay with insurance and offers generic alternatives. Epic says that feature helped save patients more than $250 million in 2025. Prescription Marketplace extends that logic beyond insurance benefit checks and into cash pricing, where the lower-cost option is sometimes hiding in plain sight.
Sometimes the self-pay price is the better price. A drug may be listed at $500 through an insurance benefit but be available for $100 cash at another pharmacy. Epic’s system is meant to reveal those differences before the patient walks out, not after a pharmacist or office staff member starts chasing down alternatives. In practical terms, this could spare patients the common sequence of abandonment, delay, and therapeutic drift that follows an unaffordable prescription.
The clinical value is not just administrative convenience. Medication adherence is a biological intervention in itself: blood pressure improves only if the antihypertensive is taken, glycemic control only if the glucose-lowering therapy is started, and symptom control only if the medication reaches the patient consistently. Price transparency does not replace clinical judgment, but it can determine whether the judgment ever becomes treatment.
Mark Cuban Cost Plus Drugs and Amazon Pharmacy Join the Build
Epic is not constructing the product in isolation. Cost Plus Drugs, the pharmacy company co-founded by Mark Cuban, and Amazon Pharmacy are among the partners helping develop the feature. Their participation suggests a broader push to connect clinicians to a market view of prescription pricing instead of forcing patients to navigate each pharmacy website on their own.
Cuban framed the use case in blunt terms: if insurance says a prescription costs $500 but the identical drug can be bought for $100 elsewhere, patients should know that before they leave the doctor’s office. The logic is hard to argue with. A medicine cannot work if the patient never fills it, and a clinician cannot adjust an unaffordable regimen if the cost difference is invisible at the point of prescribing.
Jeff Park, president of Waltz Health, welcomed the move but argued that price information alone does not solve the underlying friction. The workflow still forces clinicians and patients to sort through benefit rules, coverage limits, pharmacy selection, manufacturer programs, and available alternatives. His critique points to a deeper problem in prescription access: price comparison is helpful, but it does not automatically translate into the right choice for the right patient at the right pharmacy.
The Bedside Consequence Is Less Guesswork About Nonadherence
Epic’s own framing goes beyond savings and into diagnosis. Joel Jones, the company’s vice president of clinicals and therapeutics and patient safety officer, said the company wants to make it easier for clinicians to distinguish between a medication that failed because it was ineffective and one that failed because the patient never filled it. That distinction affects everything from treatment escalation to adherence counseling to follow-up timing.
A short paragraph captures the clinical stakes: an unfilled prescription can look exactly like treatment failure.
When a patient pays cash, the usual signals inside the electronic record can vanish. The clinician may see a drug on the med list, assume nonresponse, and choose a stronger or more complex regimen when the real problem was financial access. Price transparency at the point of care could reduce that kind of error, especially in chronic diseases where every refill gap erodes control over time.
The planned integration into MyChart also matters because it moves the cost discussion into a space patients already use. That may reduce the back-and-forth among prescribers, office staff, patients, and pharmacists that often follows a rejected or abandoned prescription. It also creates a chance to address affordability while the patient is still engaged in the visit, when substitution or therapeutic interchange remains clinically feasible.
Cash Pricing Puts Pressure on the Prescribing Model
Epic’s decision reflects a broader shift in how prescription access is being managed. Insurers, pharmacies, digital drug companies, and EHR vendors are all trying to control the moment when a medication choice becomes a payment decision. The most efficient version of that system would not make patients compare websites after the fact. It would surface the most affordable clinically appropriate option inside the ordering workflow, where the prescription is actually chosen.
Still, the launch timing leaves a long runway before the tool reaches clinicians. Summer 2027 is far enough away that implementation details, pharmacy participation, and workflow design will matter at least as much as the concept itself. Price comparison tools can fail if they arrive too late, bury the relevant data, or make the prescriber do the same manual work the patient used to do.
For now, Epic is betting that the simplest intervention can still be one of the most effective: show the price before the prescription leaves the chart. In a system where cost repeatedly interrupts care, the unresolved question is not whether patients need clearer pricing. It is whether the tool can make the lowest-cost path visible fast enough to change what gets prescribed in real time.